Antiemetics in children receiving chemotherapy

被引：20

作者：

Roila, F ^{[1
]}

Feyer, P

Maranzano, E

Olver, I

Clark-Snow, R

Warr, D

Molassiotos, A

机构：

[1] Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy

[2] Viventes Clin Beniu Needcoellin, Berlin, Germany

[3] Hosp Santa Maria, Radiat Oncol Ctr, Terni, Italy

[4] Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[5] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66103 USA

[6] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[7] Univ Manchester, Sch Nursing, Manchester M13 9PL, Lancs, England

来源：

SUPPORTIVE CARE IN CANCER | 2005年 / 13卷 / 02期

关键词：

antiemetics for children submitted to chemotherapy; dexamethasone; 5-HT3; antagonists;

D O I：

10.1007/s00520-004-0702-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not been identified. Combinations of a 5-HT3 antagonist and dexamethasone show increased efficacy with respect to 5-HT3 antagonists alone. All pediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.

引用

收藏

页码：129 / 131

页数：3

相关论文

共 10 条

[1] Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines [J].

Gralla, RJ ;

Osoba, D ;

Kris, MG ;

Kirkbride, P ;

Hesketh, PJ ;

Chinnery, LW ;

Clark-Snow, R ;

Gill, DP ;

Groshen, S ;

Grunberg, S ;

Koeller, JM ;

Morrow, GR ;

Perez, EA ;

Silber, JH ;

Pfister, DG .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2971-2994

[2] A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy [J].

Komada, Y ;

Matsuyama, T ;

Takao, A ;

Hongo, T ;

Nishimura, Y ;

Horibe, K ;

Sakurai, M .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (07) :1095-1101

[3] Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy:: a prospective randomized study [J].

Köseoglu, V ;

Kürekci, AE ;

Sorici, Ü ;

Atay, AA ;

Özcan, O .

EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (10) :806-810

[4]

Mabro M, 2000, B CANCER, V87, P259

[5] Optimal selection of antiemetics in children receiving cancer chemotherapy [J].

Roila, F ;

Aapro, M ;

Stewart, A .

SUPPORTIVE CARE IN CANCER, 1998, 6 (03) :215-220

[6] Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference [J].

Roila, F ;

Del Favero, A ;

Gralla, RJ ;

Tonato, M ;

Aapro, MS ;

Andrews, PLR ;

Ballatori, E ;

De Mulder, PHM ;

Dicato, MA ;

du Bois, A ;

Feyer, PC ;

Gandara, DR ;

Gralla, RJ ;

Gralla, RJ ;

Groshen, S ;

Grunberg, SM ;

Herrstedt, J ;

Hesketh, PJ ;

Joss, RA ;

Kris, MG ;

Marty, MM ;

Morrow, GR ;

Naylor, RJ ;

Olver, IN ;

Smyth, JF ;

Spitzer, TR ;

Stewart, A .

ANNALS OF ONCOLOGY, 1998, 9 (08) :811-819

[7] Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients [J].

Sandoval, C ;

Corbi, D ;

Strobino, B ;

Ozkaynak, MF ;

Tugal, O ;

Jayabose, S .

CANCER INVESTIGATION, 1999, 17 (05) :309-313

[8] Survey ranking of emetogenic control in children receiving chemotherapy [J].

Small, BE ;

Holdsworth, MT ;

Raisch, DW ;

Winter, SS .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (02) :125-132

[9]

Stiakaki E, 1999, PEDIATR HEMAT ONCOL, V16, P101

[10] A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy [J].

White, L ;

Daly, SA ;

McKenna, CJ ;

Zhestkova, N ;

Leal, C ;

Breatnach, F ;

Smelhaus, V ;

Hung, IJ ;

Kowalczyk, J ;

Ninane, J ;

Mitchell, T ;

Haigh, C .

PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2000, 17 (06) :445-455